<DOC>
	<DOCNO>NCT02030678</DOCNO>
	<brief_summary>A phase II study irinotecan 3 line therapy local recurrence metastatic breast cancer . Evaluate effect safety irinotecan local recurrence Metastatic breast cancer patient recieved anthracycline taxane drug . The primary endpoint Disease Control Rate Progression free survival . The second endpoint 3 4 grade Adverse Events 、overall survival.All patient recieve therapy till disease progress occurrence withdrawal standard .</brief_summary>
	<brief_title>A Phase II Study Irinotecan 3 Line More Therapy Local Recurrence Metastatic Breast Cancer</brief_title>
	<detailed_description>A phase II study irinotecan 3 line therapy local recurrence metastatic breast cancer . Evaluate effect safety irinotecan local recurrence Metastatic breast cancer patient recieved anthracycline taxane drug . The primary endpoint Disease Control Rate Progression free survival . The second endpoint 3 4 grade Adverse Events 、overall survival . irinotecan 100mg/m2 , iv , day1 , day8 , every 3cycles.If AE happens , increase irinotecan dose to125mg/m2 second cycle.All patient recieve therapy till disease progress occurrence withdrawal standard .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Mestatic breast cancer patient whose disease recurrent use anthracycline taxane drug Heart Disease.etc</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>